Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy [Phase 4]

View source ↗

Summary

Phase 4 update evaluating KW-0761 (mogamulizumab) for Mycosis fungoides or Sézary syndrome in Chinese patients who have previously received systemic therapy. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• KW-0761 (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd. | Conditions: Cutaneous T-Cell Lymphoma | Phase 4 | Status: ACTIVE_NOT_RECRUITING